logo

For the Inventor, By the Inventor

Richard Allen Houghten

Solana Beach, CA, United States of America

Richard Allen Houghten

LinkedIn

This inventor holds 93 USPTO granted patents and 5 published patent applications, primarily in Peptide Ligands (CPC class 530326). Top assignees: Torrey Pines Institute for Molecular Studies, Scripps Clinic and Research Foundation, Trega Biosciences, Inc.. Active years: 1985-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Richard Allen Houghten. Retrieved from https://idiyas.com/inventor/richard-allen-houghten

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 93 

% Patents Active = 82.8

Average Co-Inventor Count = 2.9

ph-index = 23

Forward Citations = 1,840(Granted Patents)

Forward Citations (Not Self Cited) = 1,782(Dec 10, 2025)


Inventors with similar research interests:


Location History:

  • Solhna Beach, CA (US) (1987)
  • el Mar, CA (US) (2001)
  • Solano Beach, CA (US) (2003)
  • Del Mar, CA (US) (1994 - 2008)
  • Solana Beach, CA (US) (1985 - 2013)
  • Point Saint Lucie, FL (US) (2018)
  • Vero Beach, FL (US) (2009 - 2019)
  • Port St. Lucie, FL (US) (2018 - 2024)

Company Filing History:

goldMedal35 out of 45 
 
Torrey Pines Institute for Molecular Studies
 patents
silverMedal19 out of 122 
 
Scripps Clinic and Research Foundation
 patents
bronzeMedal10 out of 22 
 
Trega Biosciences, Inc.
 patents
4. 5 out of 6 
 
Houghten Pharmaceuticals, Inc.
 patents
5. 4 out of 4 
 
Mixture Sciences, Inc.
 patents
6. 3 out of 313 
 
H. Lee Moffitt Cancer Center and Research Institute, Inc.
 patents
7. 3 out of 286 
 
Mannkind Corporation
 patents
8. 3 out of 1,993 
 
University of South Florida
 patents
9. 3 out of 723 
 
Zymogenetics, Inc.
 patents
10. 2 out of 843 
 
Louisiana State University and Agricultural & Mechanical College
 patents
11. 2 out of 22 
 
Merrion Research III Limited
 patents
12. 2 out of 2,376 
 
Regents of the University of Minnesota
 patents
13. 2 out of 1,208 
 
Scripps Research Institute
 patents
14. 2 out of 94 
 
The Burnham Institute
 patents
15. 2 out of 944 
 
The University of New Mexico
 patents
16. 2 out of 2 
 
Torry Pines Institute for Molecular Studies
 patents
17. 2 out of 16,048 
 
University of California
 patents
18. 1 out of 3,580 
 
American Cyanamid Company
 patents
19. 1 out of 605 
 
Florida International University
 patents
20. 1 out of 1 
 
Houghten Pharmaceutical Inc.
 patent
21. 1 out of 17 
 
Lion Bioscience Ag
 patents
22. 1 out of 1 
 
Lion Bioscience Science Ag
 patent
23. 1 out of 1 
 
Sarlan, Ltd.
 patent
24. 1 out of 1 
 
Torrey Pines Institute
 patent
25. 1 out of 3,058 
 
University of Florida Research Foundation Inc.
 patents
26. 1 out of 834,601 
Other
 patents
where one patent can have more than one assignee

Years Active: 1985-2024

Loading Chart...
Areas of Expertise:
Peptidomimetics
Melanocortin Ligands
KRAS Inhibitors
Neurological Disorders
Topoisomerase Inhibitors
Pain Treatment
Pharmaceutical Formulations
Receptor Ligands
Translocating Agents
Caspase Derepression
Compound Synthesis
Cyclic Compounds
93 patents (USPTO):Explore Patents
1. 11932628 - Selective small molecule peptidomimetic melanocortin ligands (2024-03-19),
2. 11352370 - Mutant KRAS inhibitors (2022-06-07),
3. 11014876 - Polyamine sulfonamides and uses thereof (2021-05-25),
4. 10899793 - Melanocortin ligands and methods of use thereof (2021-01-26),
5. 10711014 - Mutant KRas inhibitors (2020-07-14),
6. 10421764 - Mutant KRas inhibitors (2019-09-24),
7. 10258664 - Methods and compositions for treating pain (2019-04-16),
8. 10085981 - Protein acyl transferase inhibitors and methods of treatment (2018-10-02),
9. 10052309 - Bis-cyclic guanidine compound compositions, methods of use and treatment thereof (2018-08-21),
10. 10048272 - High-affinity small molecule formylpeptide receptor ligands from screening of combinatorial mixture-based libraries (2018-08-14),
11. 9994536 - Compounds and methods of treating neurological disorders (2018-06-12),
12. 9988341 - Bacterial topoisomerase inhibitors and use thereof (2018-06-05),
13. 9782388 - BIS-cyclic guanidine compound compositions, methods of use and treatment thereof (2017-10-10),
14. 9610351 - Methods and compositions for treating pain (2017-04-04),
15. 9310364 - High-affinity small molecule formylpeptide receptor ligands from screening of combinatorial mixture-based libraries (2016-04-12),

Title: Innovator Spotlight: Richard Allen Houghten

Introduction:

Richard Allen Houghten, a prolific inventor based in Solana Beach, CA, is a trailblazer in the field of oncology with an impressive portfolio of 58 patents. His groundbreaking work has significantly advanced the development of novel therapies for treating cancers involving overactive Ras signaling.

Latest Patents:

Houghten's latest patents include innovative inventions such as Mutant KRAS inhibitors and Polyamine sulfonamides. These compounds demonstrate promising antineoplastic activity and show great potential in the treatment and prevention of cancer, addressing the critical unmet medical need for effective therapeutics in oncology.

Career Highlights:

Throughout his career, Houghten has been associated with esteemed research institutions such as the Torrey Pines Institute for Molecular Studies and the Scripps Clinic and Research Foundation. His expertise and dedication to scientific advancement have led to the successful development of transformative pharmaceutical compounds.

Collaborations:

Houghten has collaborated closely with notable colleagues in his field, including John M Ostresh and Clemencia Pinilla. Together, they have worked synergistically to push the boundaries of innovation in oncology research, paving the way for new therapeutic approaches and treatment modalities.

Conclusion:

In conclusion, Richard Allen Houghten's pioneering work in oncology has significantly contributed to the advancement of cancer treatment strategies. His dedication to developing novel compounds and methodologies underscores his commitment to improving patient outcomes and addressing the unmet medical needs in the field of oncology.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…